Liu Baohai, Piao Xuehua, Guo Lianyi, Wang Guijun, Sun Weihua, Gao Leming, Zheng Xuefeng, Fang Yanli
Department of Gastroenterology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121001, China.
Department of Traditional Chinese Medicine, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121001, China.
Evid Based Complement Alternat Med. 2017;2017:7323129. doi: 10.1155/2017/7323129. Epub 2017 Nov 20.
Ulcerative colitis (UC) is a chronic lifelong inflammatory disorder of the colon. Current medical treatment of UC relies predominantly on the use of traditional drugs, including aminosalicylates, corticosteroids, and immunosuppressants, which failed to effectively control this disease's progression and produced various side effects. Here, we report a new Chinese medicine intestine formula (CIF) which greatly improved the effect of mesalazine, an aminosalicylate, on UC. In the present study, 60 patients with chronic UC were treated with oral mesalazine alone or in combination with CIF enema. The combination of mesalazine and CIF greatly and significantly improved the clinical symptoms and colon mucosal condition and improved the Mayo Clinic Disease Activity Index and health-related quality of life, when compared to mesalazine alone. In particular, the addition of CIF further decreased serum levels of tumor necrosis factor-alpha and hypersensitivity C-reactive protein but in contrast increased interleukin-4. Thus, the results demonstrate the beneficial role of CIF in UC treatment, which may be mediated by the regulation of inflammation.
溃疡性结肠炎(UC)是一种结肠的慢性终身炎症性疾病。目前UC的药物治疗主要依赖于使用传统药物,包括氨基水杨酸类、皮质类固醇和免疫抑制剂,这些药物未能有效控制该疾病的进展并产生了各种副作用。在此,我们报告一种新的中药肠道配方(CIF),它大大提高了氨基水杨酸类药物美沙拉嗪对UC的疗效。在本研究中,60例慢性UC患者接受单独口服美沙拉嗪或联合CIF灌肠治疗。与单独使用美沙拉嗪相比,美沙拉嗪与CIF联合使用可显著改善临床症状和结肠黏膜状况,并改善梅奥诊所疾病活动指数和健康相关生活质量。特别是,添加CIF进一步降低了血清肿瘤坏死因子-α和超敏C反应蛋白水平,但相反增加了白细胞介素-4水平。因此,结果证明了CIF在UC治疗中的有益作用,这可能是通过炎症调节介导的。